Medicus Pharma has announced the completion of patient enrollment for its phase 2 SKNJCT-003 trial, evaluating the safety and ...
Such public attacks might have derailed a less politically tested politician, but Zeldin has been around the block. The ...
Medicus Pharma Ltd. (MDCX) Jumps 6% in Pre-market: Following Enrollment Completion in Clinical Study
Summary • Medicus Pharma Ltd. (MDCX) rises 6% in pre-market trading, reaching $1.94 after completion of patient enrollment ...
Pyruvate dictates redox balance and cell size, establishing metabolism as a dominant regulator of cellular fitness, unveiling new strategies to modulate cancer, regeneration, and diabetes.
We explore the disconnect between mycological cure and cosmetic recovery in Tinea Versicolor, focusing on managing patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback